1-3 of 3
Alfred L. Garfall
Close
Sort by
Journal Articles

Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines

Clinical Trials & Observations
Guido Ghilardi, Luca Paruzzo, Jakub Svoboda, Elise A. Chong, Alexander A. Shestov, Linhui Chen, Ivan J. Cohen, Giulia Gabrielli, Sunita D. Nasta, Patrizia Porazzi, Daniel J. Landsburg, James N. Gerson, Jordan Carter, Stefan K. Barta, Rebecca Yelton, Raymone Pajarillo, Vrutti Patel, Griffin White, Hatcher J. Ballard, Elizabeth Weber, Ellen Napier, Emeline R. Chong, Joseph A. Fraietta, Alfred L. Garfall, David L. Porter, Michael C. Milone, Roderick O’Connor, Stephen J. Schuster, Marco Ruella
Journal: Blood Advances
Blood Adv (2024) 8 (3): 653–666.
https://doi.org/10.1182/bloodadvances.2023011492
Published: 2024
Includes: Supplemental data
Journal Articles

T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma

Alfred L. Garfall, Ehren K. Dancy, Adam D. Cohen, Wei-Ting Hwang, Joseph A. Fraietta, Megan M. Davis, Bruce L. Levine, Don L. Siegel, Edward A. Stadtmauer, Dan T. Vogl, Adam Waxman, Aaron P. Rapoport, Michael C. Milone, Carl H. June, J. Joseph Melenhorst
Journal: Blood Advances
Blood Adv (2019) 3 (19): 2812–2815.
https://doi.org/10.1182/bloodadvances.2019000600
Published: 2019
Includes: Supplemental data
Journal Articles

Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies

Clinical Trials & Observations
Adam D. Cohen, Alfred L. Garfall, Ahmet Dogan, Simon F. Lacey, Chris Martin, Nikoletta Lendvai, Dan T. Vogl, Matthew Spear, Alexander M. Lesokhin
Journal: Blood Advances
Blood Adv (2019) 3 (16): 2487–2490.
https://doi.org/10.1182/bloodadvances.2019000466
Published: 2019